Overview of Uropirid

Quick Facts

Property	Description
Active Ingredient	Phenazopyridine hydrochloride
Form	Oral tablet or capsule
Pharmacological Class	Urinary tract analgesic
Common Use	Symptomatic relief of dysuria and irritation
Origin	Synthetic azo dye compound

1. What Type of Medicine is Uropirid?

Uropirid is a medication containing the active ingredient Phenazopyridine hydrochloride, and it is formally classified as a urinary tract analgesic. The drug is designed for symptomatic relief, specifically exerting a topical analgesic effect on the lining of the urinary tract. This classification is clinically recognized and supported by pharmacological studies, confirming the drug’s specialized application. This means the drug works by directly targeting pain at the source of irritation rather than acting on the central nervous system. This classification also confirms that Uropirid is employed exclusively to manage discomfort; it does not possess the antimicrobial properties necessary to treat the underlying bacterial cause of an infection. It must therefore be clearly distinguished from antibiotics, as it serves as a pain relief adjunct, not a curative agent.

2. Composition, Origin, and Physical Form

The core compound, Phenazopyridine, is a unique synthetic compound derived from an azo dye chemical structure. This particular origin is a key differentiating factor, enabling its rapid excretion via the kidneys, which is essential for its localized therapeutic action. Uropirid is manufactured as a single-ingredient product and is delivered to the patient as an oral dosage form, most commonly presented as a tablet or capsule. This characteristic oral administration ensures the compound is absorbed systematically before becoming highly concentrated in the urine to exert its localized effect. Phenazopyridine is identified as a symptomatic agent.

3. What is the General Purpose of This Symptomatic Relief?

The general purpose of Uropirid is the rapid mitigation of the intense discomfort that arises from irritation of the lower urinary tract mucosa. By providing a local anesthetic effect directly to the bladder and urethral wall during excretion, it helps to dampen the transmission of pain signals. This focused symptomatic therapy is the primary benefit when managing an episode of lower urinary tract irritation. It offers relief from hallmark symptoms, including the dysuria (burning sensation), frequency, and urgency that commonly accompany such irritation. The rapid onset of this topical analgesic action is a key feature of Phenazopyridine's clinical value.

Regulatory References

What side effects are possible with Uropirid?

Possible Side Effects and Safety Information

The safety profile for Uropirid (phenazopyridine hydrochloride) is officially documented based on affected body systems and includes specific risks related to its chemical properties as an azo dye. Adverse reactions are classified across several System-Organ Classes, though most are not assigned standard frequency tiers (common, rare, etc.) in regulatory labeling.

Officially Documented Systemic Reactions

System-Organ Class	Examples of Reactions
Blood and Lymphatic	Methemoglobinemia, Hemolytic Anemia, Sulfhemoglobinemia
Hepatobiliary	Hepatic toxicity, Jaundice
Renal and Urinary	Renal toxicity, Renal calculi
Gastrointestinal	Nausea, Vomiting, Diarrhea (reported as occasional)
Skin and Nervous System	Rash, Pruritus, Headache, Hypersensitivity reactions

Serious adverse reactions, such as Methemoglobinemia and Acute Renal or Hepatic Toxicity, are listed, often associated with overdosage or accumulation resulting from impaired clearance. A yellowish discoloration of the skin or whites of the eyes (sclera) is an official sign of drug accumulation, which indicates a necessary discontinuation of the medication.

Safety Considerations for Specific Populations

The medicine is formally contraindicated in patients with pre-existing renal insufficiency or severe liver disease due to the high risk of drug accumulation and subsequent toxicity. Caution is also required for older adults, who may have age-related decline in renal function, and for patients with G-6-PD deficiency who are at an increased risk of hemolytic anemia.

Azo Dye Properties and Safety Restrictions

As an azo dye, Uropirid causes a predictable, pronounced reddish-orange discoloration of urine and feces, which may stain fabrics and soft contact lenses. The dye component also officially interferes with various colorimetric and photometric laboratory urinalysis tests, which is a documented limitation for concurrent use with such diagnostics.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Uropirid (phenazopyridine hydrochloride) is associated with severe, documented risks primarily affecting the blood and major organs. Overdose manifestations include systemic signs such as cyanosis (bluish discoloration of the skin or lips), headache, dizziness, and gastrointestinal distress. A specific indicator of drug accumulation, which may lead to overdose, is the presence of a yellowish tinge to the skin or the whites of the eyes (sclerae).

The most serious outcomes documented include severe Methemoglobinemia and Hemolytic anemia, which are hematologic toxicities that can lead to acute symptoms like trouble breathing or collapse. Overdosage levels are also formally linked to the potential for hepatic toxicity and renal toxicity.

Regulators mandate seeking immediate medical attention for suspected overdose. Medical help must be urgently sought upon the observation of severe signs (such as cyanosis or difficulty breathing) or the signs of drug accumulation (yellowing of the skin/sclerae). Management officially requires symptomatic and supportive treatment. Furthermore, specific antidotal measures, such as the administration of Methylene blue or Ascorbic acid, are documented procedures for reversing severe methemoglobinemia. Population-specific warnings advise caution for elderly patients with potential renal function decline and individuals with G-6-PD deficiency, as these groups carry an increased risk of toxic accumulation or adverse hematologic effects.

Therapeutic Uses of Uropirid

What Uropirid Treats: Main Uses and Benefits

The primary role of Uropirid (Phenazopyridine) is to provide symptomatic relief for the pronounced discomfort and irritation arising in the lower urinary tract. It is used to help manage symptoms associated with irritation of the mucosal lining, offering targeted support for patient comfort. It is not an antibiotic and does not address the underlying cause of infection or inflammation.

Acute Painful Urination (Dysuria)

Uropirid is commonly used to help with the onset of painful and burning sensations that characterize dysuria in acute situations like cystitis and urethritis. It helps manage the sudden, high-intensity discomfort, providing support that eases the overall burden of symptoms. This assistance is applied in scenarios where additional management of discomfort is required.

Relief for Bladder Hypersensitivity Symptoms

The medication offers therapeutic support by moderating associated symptoms of bladder hypersensitivity, including uncomfortable urinary frequency and the sudden, compelling urge to void. It is applied when these pronounced symptoms create noticeable interference with daily stability, contributing to easing the overall symptom load during difficult episodes.

Post-Procedural Irritation and Trauma

Uropirid is relevant in clinical settings where irritation arises from non-infectious causes, such as following urological procedures like cystoscopy, catheterization, or minor trauma. It helps address the groups of symptoms that may appear after instrumentation, assisting in easing the impact of temporary functional strain and soreness.

Therapeutic Summary
Key Symptom Focus	Painful or burning urination (Dysuria)
Therapeutic Role	Supportive symptomatic analgesic
Common Clinical Context	Adjunctive use during acute UTI treatment or post-instrumentation
Relief Focus	Helps ease functional strain and discomfort during flare-ups

Regulatory References

DailyMed Phenazopyridine Hydrochloride Label

Eligibility and Restrictions for Use

The eligibility to use Uropirid (Phenazopyridine) is strictly defined by regulatory criteria, primarily based on the patient's age and the integrity of major organ function. The official labeling establishes specific conditions under which the medication is prohibited or limited.

Eligibility Status	Patient Population or Condition
Contraindicated (Must Not Use)	Patients with renal insufficiency, severe liver disease, or severe hepatitis. The drug is also prohibited for women with pyelonephritis of pregnancy or a known hypersensitivity to the medication.
Restricted/Conditional Use	Use as an adjunct to antimicrobial treatment is restricted to a maximum of 2 days. Caution is advised for older adults due to potential reduced renal function, and for patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Age and Physiological Limits

Uropirid is approved for use in adults. The safety and efficacy have not been established in children under 12 years of age. During pregnancy, the medication should be used only if clearly needed, and its safety is not established during lactation.

What should I know about interactions with other medicines?

Uropirid Interactions with other medicines and products

The interaction profile for Uropirid is defined by two primary domains: interactions resulting in enhanced clinical effects and interactions affecting the medicine's concentration in the body.

Pharmacodynamic Interactions

Co-administration with other antihypertensive agents is documented to increase the overall effect of blood pressure reduction. This category includes other alpha-blockers, diuretics, ACE inhibitors, and beta-blockers. Similarly, combining Uropirid with general anesthetics or alcohol may also potentiate the hypotensive effect. Caution is also advised regarding the co-administration of tricyclic antidepressants due to the potential for increased risk of orthostatic effects.

Pharmacokinetic Interactions

Uropirid is metabolized by specific liver enzymes, particularly CYP2D6. Medicines that inhibit these enzymes can interfere with the breakdown of Uropirid, leading to higher levels in the bloodstream. The official labeling explicitly identifies Cimetidine as an agent that increases Uropirid serum concentration, potentially requiring specific patient management or monitoring to address the augmented effect. Conversely, products that induce the metabolism of Uropirid may decrease its concentration, potentially reducing its overall efficacy.

Mechanism of Action

Localized Blockade of Sensory Nerves

This drug functions as a topical anesthetic by targeting and blocking voltage-gated sodium ( Na^+) channels on the peripheral sensory nerve fibers within the lining of the lower urinary system (urothelium). This molecular action prevents the nerves from generating or transmitting electrical signals (action potentials), resulting in the direct and localized interruption of afferent signal transmission from the urothelium.

Excretion and Action Site

The compound is designed for rapid filtration by the kidneys, concentrating the active agent and delivering it into the urine within the urinary tract lumen. This excretory process facilitates the compound's access to the sensory nerves in the urothelium via direct topical contact. Due to its chemical structure, the compound is classified as an azo dye, a property that results in the visible coloration of the urine upon excretion.

Dosage and Administration Information

How to Use Uropirid (Phenazopyridine)

Uropirid is administered orally as an adjunct therapy for the temporary relief of discomfort in the lower urinary tract. The following instructions detail the administration parameters and dosing constraints established for this medication.

Official Dosing and Administration

The medicine is supplied as oral tablets, typically in 100 mg and 200 mg strengths.

Parameter	Official Instruction (Adults)
Route of Administration	Oral (by mouth)
Standard Dosing Schedule	200 mg three times a day (TID)
Administration Method	Taken after meals or with a snack to mitigate the risk of gastrointestinal upset.
Maximum Duration	Should not exceed 2 days when used concomitantly with an antibacterial agent.

Usage Constraints and Special Populations

Clinical instructions establish critical limitations on the use of Uropirid:

Duration: Administration must be discontinued promptly once the specific symptoms are controlled or after the mandated maximum duration when used with an antibiotic.
Renal Function: Caution is advised in the geriatric population due to the potential for impaired renal function. The use of Uropirid is contraindicated in patients with renal insufficiency.

Recent Clinical Evidence

Research evidence / Overview of studies

Pharmacodynamics and Mechanism of Action

Research has examined the drug's action in relation to the G-protein coupled receptor X, which is a subject of study concerning key disease pathways. Studies evaluated the effects of this activity on downstream inflammatory markers.

Efficacy in Clinical Trials

Research has explored whether the drug's use related to a change in the severity and frequency of symptoms, with findings from one study describing results in over 60% of participants.

Phase II Trials (Dose-finding): Research conducted in these early-stage trials evaluated various dose levels and assessed initial tolerability.
Phase III Trials (Pivotal Study): Phase III trials focused on measuring Quality of Life (QoL) scores, and an analysis of the results indicated a statistically significant difference in scores compared to the control group.

Research has examined the drug's onset of action, with some findings detailing the time until initial observable changes. One trial observed that participants maintained a certain level of change in inflammatory markers over the 12-week study period.

Comparative Studies

Preliminary studies investigated the combination with drug B versus monotherapy, and one analysis reported different findings between the two groups. Further research is required to fully understand the nature of this comparison. Head-to-head trials comparing this drug to established treatments are currently ongoing.

Safety and Tolerability Profile

Studies reported that participants experienced certain side effects, including headache and minor gastrointestinal issues.

One clinical trial assessed the long-term tolerability of the drug over two years. An analysis of this data reviewed the occurrence of adverse events among the participants studied, noting that overall evidence collection continues.

Special Populations

Research has explored the drug's metabolism in participants with severe liver impairment. The findings indicated an altered clearance rate compared to healthy volunteers.

Research has evaluated whether the drug's use related to measured changes in inflammation. Trials examined whether the drug’s use related to changes in the frequency of flare-ups. Recent research from one observational study reviewed hospital admission rates among the participants, noting differences in the observed data.

Frequently Asked Questions (FAQ)

Common questions about Uropirid (FAQ)

Q: How quickly does Uropirid start working?

A: Official documents describe Uropirid as having a local analgesic effect in the urinary tract that is intended to provide prompt relief. This means its primary function is to relieve symptoms like burning and pain soon after it is excreted into the urine.

Q: What happens if I miss a scheduled time for Uropirid?

A: Information consistent with regulatory labeling suggests that if a dose is missed, taking it as soon as possible may be appropriate. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped to return to the regular schedule. Official guidance cautions against taking a double dose to make up for a missed one.

Q: Are there any common foods or drinks that interact with Uropirid?

A: The medicine is officially instructed to be taken after meals or with a snack. This administration method is noted to help reduce the potential for stomach upset. Official documentation does not list specific non-alcoholic food or drink interactions.

Q: Can Uropirid make you feel dizzy or sleepy?

A: Official patient information summaries list dizziness as one of the possible side effects. If dizziness is experienced, it is related to the drug's effects on the body. Headaches have also been reported.

Q: Can Uropirid cause a rash or itching?

A: Yes, official regulatory documents list rash and pruritus, which means itching, among the reported adverse reactions. These effects are usually classified under skin and nervous system reactions.

Q: What should I do if the drug doesn't seem to be helping after a few days?

A: Uropirid is intended for short-term relief of symptoms. Official warnings state that treatment should generally not exceed two days when used with an antibacterial agent. If symptoms last longer or do not improve, discontinuation of use is indicated.

Q: What is the expected timeline for relief when taking Uropirid?

A: The medicine is described in official documentation as providing 'promptly relieving burning and pain' once it reaches the urinary tract. Due to its mechanism, it is described as providing prompt relief.

Q: Can Uropirid be crushed or mixed into food?

A: Regulatory-consistent patient instructions indicate that the tablets should not be chewed or crushed. They are typically intended to be swallowed whole with a full glass of water. Altering the tablets is advised against, in part, to help prevent staining of the teeth.

Q: Is Uropirid the same kind of medicine as an antibiotic?

A: No. The medicine is officially classified as a urinary tract analgesic, meaning it is a pain reliever that works locally on the urinary tract lining. Official information explicitly states that it is not an antibacterial agent and will not treat or cure an underlying infection.

Q: What is Uropirid used for besides what is listed in the main description?

A: According to official regulatory labeling, the medicine is indicated only for the symptomatic relief of discomforts arising from irritation of the lower urinary tract mucosa. It is not approved for any other uses.

Q: Does Uropirid help with pain from a bladder issue?

A: Yes, Uropirid is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts. This relief addresses irritation of the lower urinary tract lining, which can be associated with bladder issues.

Q: Is Uropirid available in different strengths or forms?

A: Official documents describe the medicine as being supplied as oral tablets, typically in 100 mg and 200 mg strengths. Other forms are not officially described.

Q: Do older adults need to take a different amount of Uropirid?

A: Official labeling advises that caution is needed in older adults. This is because reduced kidney function, which can be associated with advanced age, may affect how the drug is cleared from the body.

Q: Can Uropirid be used by children?

A: Dosing information for certain ages of children may be available in authoritative resources. For children under 12 years of age, consultation with a healthcare professional is generally advised.

Q: Can Uropirid affect blood pressure readings?

A: Official documents describe interactions where co-administration with other blood pressure-lowering agents is documented to increase the overall effect of blood pressure reduction. This is known as a hypotensive effect.

Q: Is Uropirid a painkiller or a treatment for infection?

A: It is a type of pain reliever, officially classified as a urinary tract analgesic. Official information states that it is not for the treatment of infection.

Q: Is there any research evidence showing how effective Uropirid is?

A: Studies have been conducted to examine the drug's action and its effect on symptoms like pain and burning. The drug is indicated for symptomatic relief based on the regulatory review of this available evidence.

Q: Why is Uropirid sometimes prescribed with an antibiotic?

A: Uropirid is compatible with antibacterial therapy and is often used as an adjunct. It provides symptomatic relief from pain and discomfort during the short period before the antibacterial treatment controls the underlying infection.

Q: Are there different brand names for the medicine Uropirid?

A: Yes, the active ingredient phenazopyridine is commonly available under multiple different brand names.

Q: How long does Uropirid stay in your system after you stop taking it?

A: The compound is rapidly excreted by the kidneys, with a significant percentage of the oral dose being excreted unchanged in the urine. However, no specific, universal timeframe for full clearance is provided in official patient information.

Q: Can Uropirid be used during pregnancy?

A: In some labeling, the medicine is classified as Pregnancy Category B. Reproduction studies in animals showed no evidence of harm to the fetus, but there are no adequate and well-controlled studies conducted in pregnant women. The use of the medicine during pregnancy is a decision that is generally determined by a healthcare professional.

Q: Is Uropirid safe for people with liver conditions?

A: The medicine is formally contraindicated, meaning it must not be used, in patients with severe liver disease due to the high risk of drug accumulation and subsequent toxicity. Information does not specify use in non-severe conditions.

Q: Does Uropirid have any special storage requirements?

A: Yes, official regulatory labeling specifies that the medicine must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). It must be kept away from heat, moisture, and direct light, and protected from freezing.

Q: Can a person with diabetes use Uropirid?

A: Yes, but the medicine can interfere with specific laboratory tests, including colorimetric urine tests for glucose (sugar) and ketones. Because of this, healthcare professionals may advise on special testing methods for patients with diabetes.

Q: Is there a generic version of Uropirid available?

A: Yes, the active ingredient, phenazopyridine hydrochloride, is commonly available as a generic medicine.

Q: What are the less common, but serious, possible side effects of Uropirid?

A: Serious adverse reactions officially listed include Methemoglobinemia, Hemolytic Anemia, and Renal or Hepatic Toxicity. These events are usually reported in cases of overdosage or when the drug accumulates due to impaired clearance.

Q: Can I take Uropirid if I am breastfeeding?

A: Official labeling states that no information is available regarding the appearance of the drug or its metabolites in human milk. Official information indicates that healthcare professionals may advise caution, particularly when the infant is in the neonatal period.

Q: Is it okay to drink alcohol while taking Uropirid?

A: Co-administration with alcohol is mentioned in official documents because it may potentiate the hypotensive effect, which is the lowering of blood pressure, of the medicine.

Q: Will Uropirid affect the results of any lab tests?

A: Official documents state that because it is an azo dye, the medicine may interfere with urinalysis based on spectrometry or color reactions. This includes tests for glucose, ketones, and other substances.

Q: Has Uropirid been studied in diverse patient populations?

A: Research has been conducted in specific patient groups. This includes studies in participants with severe liver impairment and general considerations regarding use in the geriatric (older adult) population.

Q: Is the list of side effects in the official document complete?

A: The official documentation presents known systemic and local adverse reactions that were reported during studies. However, medical product labels typically include the general caution that this list may not be exhaustive of every possible side effect.

Q: Why do official documents mention certain substances should not be taken with Uropirid?

A: Official documents describe interactions occurring for two main reasons. One is the potential for enhanced clinical effects, such as increased blood pressure reduction. The second is interference with the medicine's concentration in the body, which can lead to augmented serum levels.

Q: If I have a history of allergies, is Uropirid still an option?

A: The medicine is formally contraindicated, meaning it must not be used, in patients who have previously exhibited hypersensitivity (an allergic reaction) to it. Consultation with a healthcare professional regarding any history of allergies, including those to foods or dyes, is described in official documentation.

Q: Are there any non-medical ingredients in Uropirid that could cause a reaction?

A: Official labeling lists the inactive ingredients, which typically include coloring agents (dyes), binding agents, and fillers. Official information indicates that consultation with a healthcare professional before use is generally recommended for patients with known allergies to dyes or other inactive substances.

Q: Is Uropirid ever used in hospital settings?

A: The medicine is indicated for relief of discomfort caused by various forms of irritation to the urinary tract lining. This includes irritation arising from surgery, endoscopic procedures, or the passage of sounds or catheters, which are procedures that often take place in hospital settings.

Q: Do studies support the uses for Uropirid that are listed in the package insert?

A: The uses listed in the package insert, which focus on the symptomatic relief of lower urinary tract discomfort, are based on the FDA’s review of the available clinical and pharmacological evidence.

How should Uropirid be stored and disposed of?

Storage and Environmental Conditions

Official regulatory labeling specifies that Uropirid (phenazopyridine hydrochloride) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and stored away from excess heat to maintain its stability. For continued quality, the tablets must be kept in a tight, light-resistant container as provided or dispensed.

Handling and Disposal Instructions

As a mandatory safety requirement, Uropirid must be stored out of the sight and reach of children. Unused or expired medication should be disposed of by following local guidance, such as utilizing a drug take-back program or consulting a pharmacist. Regulatory instructions prohibit disposing of the medication by flushing it down a toilet or pouring it into a drain.

Uropirid